Innoviva (INVA) Cash & Current Investments (2010 - 2026)
Innoviva (INVA) posted Cash & Current Investments of $603.1 million for Q1 2026, up 9.46% on a QoQ basis from $550.9 million in Q4 2025, and up 89.0% year-over-year from $319.1 million in Q1 2025.
Innoviva (INVA) Cash & Current Investments (2010 - 2026) Analysis & Trends
Innoviva's Cash & Current Investments history runs 17 years deep, the most recent figure standing at $603.1 million for Q1 2026.
- Quarterly Cash & Current Investments rose 89.0% year-over-year to $603.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $603.1 million (up 89.0% YoY) and the FY2025 annual result came in at $550.9 million, up 80.66% from the prior year.
- Cash & Current Investments was $603.1 million for Q1 2026 at Innoviva, up from $550.9 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $603.1 million in Q1 2026 and bottomed at $144.0 million in Q1 2023.
- A 5-year average of $299.5 million and a median of $283.6 million in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 555.45% — and 2023, when it sank 40.21%.
- Innoviva's Cash & Current Investments stood at $291.0 million in 2022, then tumbled by 33.51% to $193.5 million in 2023, then surged by 57.59% to $305.0 million in 2024, then surged by 80.66% to $550.9 million in 2025, then climbed by 9.46% to $603.1 million in 2026.
- Business Quant data shows INVA's Cash & Current Investments at $603.1 million in Q1 2026, $550.9 million in Q4 2025, and $476.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Innoviva | 1.58 Bn | 979.49 Mn | 75.83 Mn | 603.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 603.09 Mn |
| Dec 31, 2025 | 550.94 Mn |
| Sep 30, 2025 | 476.51 Mn |
| Jun 30, 2025 | 397.53 Mn |
| Mar 31, 2025 | 319.09 Mn |
| Dec 31, 2024 | 304.96 Mn |
| Sep 30, 2024 | 260.63 Mn |
| Jun 30, 2024 | 217.00 Mn |
| Mar 31, 2024 | 178.36 Mn |
| Dec 31, 2023 | 193.51 Mn |
| Sep 30, 2023 | 180.00 Mn |
| Jun 30, 2023 | 173.03 Mn |
| Mar 31, 2023 | 144.05 Mn |
| Dec 31, 2022 | 291.05 Mn |
| Sep 30, 2022 | 301.07 Mn |
| Jun 30, 2022 | 283.58 Mn |
| Mar 31, 2022 | 216.80 Mn |
| Dec 31, 2021 | 201.53 Mn |
| Sep 30, 2021 | 135.12 Mn |
| Jun 30, 2021 | 43.27 Mn |